Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition

Table 2 Univariate analyses for factors associated with recurrence and survivals

Factor	Recurrence		P value	RFS (%)	P value	OS (%)	P value
	Yes	No
Age (yr)
≤ 57	19	16	0.184	53.2	0.211	66.7	0.135
> 57	18	9		38.1		50.6
Gender
Male	26	21	0.469	58.9	0.192	55.4	0.633
Female	9	6		42.3		64.8
Etiology			0.235		0.659		0.835
HBV infection	27	19		45.7		56.3
HCV infection	7	4		39.2		54.5
Alcohol	2	3		58.4		61.7
Background liver pathology			0.953		0.784		0.947
Normal liver	2	1		55.3		63.5
Chronic hepatitis	13	7		45.6		57.4
Liver cirrhosis	22	17		40.9		50.2
AFP (ng/mL)
≤ 197	15	18	0.084	58.3	0.038	65.5	0.074
> 197	19	10		29.6		42.8
ALT (U/L)
≤ 66	15	13	0.371	45.6	0.881	55.3	0.942
> 66	19	15		41.5		52.9
Child-Pugh
A	24	20	0.774	40.2	0.695	54.1	0.133
B	11	7		38.8		44.3
Tumor size (cm)
≤ 5	21	20	0.417	52.9	0.024	68.3	0.014
> 5	14	7		31.7		44.8
Tumor number
Single	25	18	0.217	47.1	0.052	58.3	0.233
Multiple	13	6		30.2		46.5
Vascular invasion
No	31	20	0.042	54.6	0.019	62.8	0.008
Yes	8	3		31.8		40.9
Tumor encapsulation
Yes	14	10	0.649	47.6	0.443	65.3	0.032
No	23	15		38.2		43.1
Tumor differentiation
I + II	21	24	0.241	45.3	0.695	59.6	0.047
III + IV	11	6		41.8		40.1
TNM stage
I	19	21	< 0.001	56.8	< 0.001	66.4	< 0.001
II + III	18	4		20.4		35.7
CCL20
Low	13	19	< 0.001	60.9	< 0.001	70.1	< 0.001
High	27	3		21.4		30.6

AFP: Alpha fetoprotein; ALT: Alanine aminotransferase; CCL20: Chemokine ligand 20; HBV: Hepatitis B virus; HCV: Hepatitis C virus; OS: Overall survival; RFS: Recurrence-free survival; TNM: Tumor-node-metastasis.